Wikipedia

Phillip D. Zamore

Phillip D. Zamore is an American molecular biologist and biochemist who co-developed the first in vitro system for studying the mechanism of RNA interference (RNAi). He is the Gretchen Stone Cook Professor of Biomedical Sciences[1] at University of Massachusetts Chan Medical School, Worcester, Massachusetts. Zamore is chair of the RNA Therapeutics Institute (RTI), established in 2009, and has been a Howard Hughes Medical Institute Investigator since 2008.[2]  

Phillip D. Zamore
Alma materHarvard University, Whitehead Institute
Scientific career
FieldsBiochemistry, molecular biology
InstitutionsUniversity of Massachusetts Chan Medical School, Howard Hughes Medical Institute
Websitezamorelab.umassmed.edu

Research

edit

The Zamore lab seeks to understand the molecular mechanisms and biological functions of RNAi and related pathways in animals, including how small RNAs (microRNAs, small interfering RNAs, and PIWI-interacting RNAs) regulate gene expression and suppress transposons.[3] In addition to a focus on basic research, the Zamore lab is working to develop novel nucleic acid-based drugs to treat human disease.[2] Dr. Zamore has more than 60,000 citations on Google Scholar.[4]

Biography

edit

Zamore received his A.B. in biochemistry and molecular biology from Harvard University in Cambridge, Massachusetts, in 1986 and continued graduate studies with Michael Green at Harvard, receiving his Ph.D. in 1992.[1] After completing postdoctoral studies at The Whitehead Institute for Biomedical Research, MIT, and the Skirball Institute at New York University Medical Center with Ruth Lehmann, James R. Williamson, and David Bartel, Zamore began his academic career as an assistant professor in the Department of Biochemistry and Molecular Pharmacology in 1999 at UMass Medical School in Worcester, Massachusetts. A member of the National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences, Zamore has trained 40 PhD and MD/PhD students and post-doctoral scholars.

Involvement with biotechnology

edit

Zamore's research has led to a career in biotechnology, co-founding Alnylam Pharmaceuticals in 2002.[5] Alnylam is dedicated to bringing RNAi based therapies to market and developed the first-ever FDA approved RNAi drug, Patisiran, gaining FDA approval in August 2018.[6] In 2014, Dr. Zamore co-founded another RNAi based company; Voyager Therapeutics,[7] which focuses on developing therapeutics for neurodegenerative disorders.

Selected awards and honors

edit
  • RNA Society / Cold Spring Harbor Laboratory Press Distinguished Research Mentor Award, 2024
  • Member, National Academy of Medicine, 2023[8]
  • Member, National Academy of Sciences, 2023[9]
  • Fellow, American Academy of Arts and Sciences, 2023[10]
  • Invented Here! Honoree, Boston Patent Law Association, for US patent US 9,226,976, “RAAV- Based Compositions and Methods for Treating Alpha-1 Anti-Trypsin Deficiencies,” 2017
  • Paper of the Year (Salomon et al., Cell 2015), Oligonucleotide Therapeutics Society[11]
  • Chancellor's Medal for Excellence in Scholarship, University of Massachusetts Medical School, 2014[12]
  • “The World’s Most Influential Scientific Minds 2014,” Molecular Biology & Genetics, Thomson-Reuters[13]
  • Top 20 Translational Researchers of 2014, Nature Biotechnology[14]
  • Fellow, National Academy of Inventors, 2014[15]
  • Outstanding Research Achievement, Nature Biotechnology SciCafé, 2009
  • Schering-Plough Award, American Society of Biochemistry and Molecular Biology, 2009
  • Most Highly Cited Researchers, 2002–2012 (Thomson-Reuters)[1]
  • W.M. Keck Foundation Young Scholar in Medical Research, 2002–2007
  • Top 20 Most Highly Cited Researchers in Molecular Biology and Genetics, 2002–2006, ScienceWatch (Thomson Scientific)[2]
  • Pew Scholar in the Biomedical Sciences, 2000–2004[16]

Selected publications

edit

References

edit
  1. ^ a b c "Phillip Zamore | Profiles RNS". profiles.umassmed.edu. Retrieved 2018-10-30.
  2. ^ a b c "Phillip D. Zamore, PhD". HHMI.org. Retrieved 2018-10-30.
  3. ^ "Phillip Zamore's Laboratory". Phillip Zamore's Laboratory. Retrieved 2018-11-09.
  4. ^ "Phillip D. Zamore - Google Scholar Citations". scholar.google.com. Retrieved 2018-10-30.
  5. ^ "Alnylam SAB".
  6. ^ "FDA approval of Alnylam drug is first ever for RNAi-based therapy - STAT". STAT. 2018-08-10. Retrieved 2018-10-30.
  7. ^ "Founders". Voyager Therapeutics. Retrieved 2018-10-30.
  8. ^ "National Academy of Medicine Elects 100 New Members". October 9, 2023.
  9. ^ "2023 NAS Election". www.nasonline.org. Retrieved 2023-05-09.
  10. ^ "New Members". American Academy of Arts & Sciences. Retrieved 2023-05-01.
  11. ^ "Paper of the Year - Oligonucleotide Therapeutics Society". Oligonucleotide Therapeutics Society. Retrieved 2018-10-30.
  12. ^ "Chancellor's Medals". University of Massachusetts Medical School. 2014-03-31. Retrieved 2018-10-30.
  13. ^ "Three UMMS scientists named in 2014 Thomson Reuters Report on most influential scientific minds". University of Massachusetts Medical School. 2014-07-10. Retrieved 2018-10-30.
  14. ^ Huggett, Brady; Paisner, Kathryn (2015). "Top 20 translational researchers of 2014". Bioentrepreneur. 33 (9): 897. doi:10.1038/bioe.2015.9. PMID 26349903.
  15. ^ "Search Fellows - National Academy of Inventors". academyofinventors.org. Retrieved 2018-10-30.
  16. ^ "Phillip D. Zamore, Ph.D." www.pewtrusts.org. Retrieved 2018-11-09.
Retrieved from "https://en.wiki.x.io/w/index.php?title=Phillip_D._Zamore&oldid=1221398140"